TABLE 2.

Outcomes of published studies using VEGFR inhibitors for the treatment of recurrent glioblastoma

Authors & Year	Study Type & Trial Phase	No. of Patients	Prior Treatment	Current Intervention & Regimen	Radiographic Response	PFS	OS
cediranib	BBB permeability: good but active efflux out via transporter
Batchelor et al,   2010	Phase II clinical trial,  single arm	31	variable	cediranib	PR (57%), minor (20%)	26% at 6 mos	7.6 mos
Batchelor et al,   2013	Phase III clinical trial,  randomized, pla-  cebo controlled,  partially blinded	325: cediranib (n = 131),  cediranib, lomustine  (n = 129), lomustine,  placebo (n = 65)	radiotherapy,  temozolomide	cediranib or cedi-  ranib + lomustine  or lomustine +  placebo	cediranib: CR (1%), PR (14%), SD  (64%), PD (9%); cediranib + lomus-  tine: CR (2%), PR (16%), SD (55%),  PD (16%); lomustine + placebo: CR  (0%), PR (9%), SD (41%), PD (41%)	cediranib: median 92 days;  cediranib + lomustine:  median 125 days;  lomustine + placebo:  median 82 days	cediranib: 8.0 mos;  cediranib +  lomustine: 9.4  mos; lomustine +  placebo 9.8 mos